PDCD1 and neoplasm: At Week 12, a tumor response was observed in 14 of 98 (14.3%; 95% CI: 8.70%-22.8%) treatment-naive MM patients (corresponding to 14 patients treated with anti-PD1), versus 4 of 53 (7.5%; 95% CI: 2.1%-18.2%) patients who were previously treated (p=0.34).